Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision oncology. Among the highlights is the MONSTAR-SCREEN-3 study, which demonstrates the power of Myriad Genetics, Inc. (NASDAQ:MYGN)’s whole-genome sequencing-based Precise MRD test to detect circulating tumor DNA (ctDNA) with unprecedented sensitivity across multiple cancer types, achieving 100% baseline detection and identifying tumor fractions as low as 0.0001%. This technology also flags cancer recurrence earlier than traditional imaging.

A biotechnologist in a laboratory testing an Immuno-oncology treatment.

Other studies include ultrasensitive ctDNA monitoring in metastatic breast cancer, ancestry-specific cancer risk variants, and expanded genetic testing for hereditary cancers. Myriad Genetics, Inc. (NASDAQ:MYGN) also announced upcoming launches: a commercial Precise MRD test in 2026, an AI-powered Prolaris prostate cancer test with PATHOMIQ, and an expanded MyRisk hereditary cancer panel.

Full integration with leading EMR platforms like Flatiron’s OncoEMR and Epic is planned for later this year, further streamlining clinical workflows.

While we acknowledge the potential of MYGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than MYGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.